VIAL
Compound comparison

BPC-157 vs TB-500

BPC-157 and TB-500 are both recovery compounds evaluated on Vial: BPC-157 is not FDA approved for human use with preclinical evidence, and TB-500 is not FDA approved for human use with preclinical evidence, offered by 14 and 4 verified providers respectively.

Vial summary · compiled from public records

At a glance

BPC-157

Category
Recovery
FDA / legal status
Gray Market
Route
Subcutaneous
14providers on Vial →

TB-500

Category
Recovery
FDA / legal status
Gray Market
Route
Subcutaneous
4providers on Vial →

Side by side

FieldBPC-157TB-500
CategoryRecoveryRecovery
Brand names
FDA / legal statusGray MarketGray Market
Evidence tierPreclinicalPreclinical
Administration routeSubcutaneousSubcutaneous
Compounding accessNot FDA approved, limited regulated accessNot FDA approved, limited regulated access
Providers on Vial14 listed4 listed
Typical price band$$$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About BPC-157

A synthetic 15-amino-acid peptide derived from human gastric juice proteins, BPC-157 (Body Protection Compound-157) demonstrates cytoprotective and regenerative properties in preclinical studies. Research in animal models suggests it may accelerate healing of tendons, ligaments, muscle, and gastrointestinal tissue through mechanisms involving angiogenesis, growth factor modulation, and nitric oxide pathway regulation. While extensively studied in rodent injury models, human clinical trial data remains limited, and the compound is not currently approved for therapeutic use by major regulatory agencies.

About TB-500

A synthetic peptide fragment derived from Thymosin Beta-4, this compound functions as an actin-sequestering protein that promotes cell migration, angiogenesis, and tissue repair. Its mechanism involves upregulating cell-building proteins and reducing inflammation at injury sites. Research applications have focused primarily on wound healing, cardiac tissue repair following ischemic injury, and musculoskeletal recovery in preclinical models.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.